COPENHAGEN (Reuters) -The CEO of Novo Holdings said on Tuesday the controlling shareholder of Danish drugmaker Novo Nordisk is ready for a huge windfall from the runaway success of weight-loss drug Wegovy. Novo Holdings invests and manages the wealth and assets of the Novo Nordisk Foundation, whose newly bulging coffers could make it a major philanthropic player and environmental, social and governance (ESG) investor. Referring to estimates that Wegovy and other drugs will generate returns of more than $12 billion in the coming years, Novo Holdings CEO Kasim Kutay said: "If these forecasts are correct, that's a hell of a lot of money coming our way over the next decade and hopefully more."